LC8 Stock Overview
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Calliditas Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €17.83 |
| 52 Week High | €18.37 |
| 52 Week Low | €7.18 |
| Beta | 1.46 |
| 11 Month Change | -0.11% |
| 3 Month Change | 2.47% |
| 1 Year Change | 117.04% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 149.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| LC8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.4% | 1.4% | 0.8% |
| 1Y | 117.0% | -18.4% | 9.1% |
Return vs Industry: LC8 exceeded the German Pharmaceuticals industry which returned -13.1% over the past year.
Return vs Market: LC8 exceeded the German Market which returned 14% over the past year.
Price Volatility
| LC8 volatility | |
|---|---|
| LC8 Average Weekly Movement | 0.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LC8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LC8's weekly volatility has decreased from 12% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 222 | Renee Aguiar-Lucander | www.calliditas.se |
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) Fundamentals Summary
| LC8 fundamental statistics | |
|---|---|
| Market cap | €11.18b |
| Earnings (TTM) | -€42.36m |
| Revenue (TTM) | €141.20m |
6.8x
P/S Ratio-22.7x
P/E RatioIs LC8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LC8 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.60b |
| Cost of Revenue | SEK 104.68m |
| Gross Profit | SEK 1.50b |
| Other Expenses | SEK 1.98b |
| Earnings | -SEK 480.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | -8.89 |
| Gross Margin | 93.46% |
| Net Profit Margin | -30.00% |
| Debt/Equity Ratio | 920.0% |
How did LC8 perform over the long term?
See historical performance and comparison